MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a leading pre-clinical-stage pharmaceutical development company, is excited to announce that its novel oral ketamine analog, Ketamir-2, has shown greater pain ...
The FDA stated its concerns over patients using compounded GLP-1s for weight loss earlier this year. Compounded drugs are not FDA approved, and the agency warned consumers about adverse events related ...